What separates a pharma launch that captures market share from one that spends twelve months in recovery mode — and how to build the planning architecture that gets it right from day one.
Executive Summary (TL;DR)
The Planning GapMost Indian pharma brands approach new drug launches without a structured GTM framework — treating segmentation, messaging, and channel decisions as isolated activities rather than interconnected layers.
The 5-Layer Model: A rigorous go-to-market strategy for pharma integrates five distinct but interdependent layers — market segmentation, channel mix planning, scientific messaging, payer access, and launch sequencing — with each layer directly shaping the one that follows.
The Competitive Advantage: Brands that plan their GTM strategy as an integrated system consistently reach peak sales faster than those that plan in silos, and spend significantly less on post-launch repositioning to correct misfires.
Pharma & Life Sciences Practice • Brand Strategy Intelligence
Fig 1. A pharma brand team maps a five-layer GTM framework before a new molecule launch in the Indian market.
Most pharma brands build their go-to-market strategy in reverse. They select a channel, brief a medical representative team, and begin distributing promotional materials — only to discover three months post-launch that the wrong healthcare professionals (HCPs) are prescribing the molecule, for patients outside the intended profile, at a price point that payers will not support.
A structured go-to-market strategy for pharma is not a launch checklist. It is an integrated planning architecture that connects patient segmentation to prescriber targeting, scientific narrative to commercial messaging, and market access planning to field deployment — before a single rep walks into a physician’s clinic.
India’s top pharmaceutical companies now face a defining set of pressures. Competition from domestic generics and biosimilar manufacturers, tightening CDSCO regulatory timelines, and rising HCP expectations for scientific depth all demand more disciplined commercial planning than the industry has historically delivered. Leading Indian pharma brands are now adopting the 5-layer framework outlined in this article to stress-test every launch decision before it reaches the field — replacing reactive commercial planning with integrated strategic architecture.
A pharma GTM plan without rigorous segmentation is directional at best. Layer 1 defines who you are selling to — not as a generic therapeutic area, but as a specific patient population, a specific prescriber profile, and a specific set of clinical situations where your molecule delivers differentiated value.
Begin with the patient. Define the precise disease subtype, line of therapy, and comorbidity profile where your product’s clinical evidence is strongest. This is a scientific discipline: the Target Product Profile (TPP) carries the clinical evidence, and the segmentation exercise translates that evidence into actionable patient segments. In India, mapping this against real-world epidemiological data often reveals that tier-2 and tier-3 city burden data surfaces patient populations that metro-centric planning misses entirely.
Once the patient segment is defined, map backwards to the prescriber. Identify which specialists or GPs manage this patient profile in India and what influences their prescribing decisions—be it clinical trial data, medical society guidelines, or KOL endorsement. Prioritise HCPs by prescribing potential, not just volume; a mid-volume specialist in a therapeutic niche where your molecule’s differentiation is clearest often delivers higher incremental value than a high-volume prescriber in a crowded market.
An effective HCP targeting strategy at this layer should produce a tiered prescriber list:
"Approximately 40–50% of new drug launches in emerging markets, including India, fall short of first-year revenue targets. Industry benchmarking consistently identifies poor HCP targeting and misaligned channel mix — not product quality — as the primary drivers of launch underperformance."
Historically, Indian pharma relied almost exclusively on field-force detailing. While that model still works, it no longer works alone. A functional GTM channel mix today must be calibrated by HCP tier, specialty, and geography to avoid the expensive mistake of a “one-size-fits-all” approach.
An effective mix integrates at least three engagement modes:
Rep-to-Digital Ratio: One of the most practical outputs of Layer 2 is calculating an explicit engagement ratio. Since field resources are finite, brands that set digital KPIs and adjust them based on real-time data achieve a far better return on promotional spend.
The scientific message is the engine of your GTM strategy. Without a clear, evidence-grounded narrative, the best segmentation and channel mix will not move prescribing behaviour. Layer 3 defines what you say and to whom.
The narrative must be grounded in clinical trial data—Phase III endpoints, sub-group analyses, and RWE—validated by medical affairs. For the Indian market, it is vital to integrate local clinical context, such as dosing requirements or tolerability profiles specific to Indian populations, to increase prescriber confidence.
Ready to structure your launch messaging around a differentiated scientific narrative?
Explore OneAlphaMed’s Brand Strategy & Product Launch services →Treating payer access as an afterthought is a critical strategic error. Layer 4 requires mapping the landscape and shaping the market before commercial teams encounter pricing barriers.
India’s environment is fragmented, ranging from government programmes like PM-JAY to corporate health plans and out-of-pocket segments. For premium branded products, the access argument must be economic—using HEOR data and cost-effectiveness models to support value negotiations with formulary committees.
Market shaping involves building clinical awareness and diagnostic readiness before the product is available. This includes KOL advisory boards and disease awareness initiatives that ensure the market understands the clinical need long before the product arrives.
Launch sequencing is a strategic decision about which stakeholders and enablers must be activated first to deliver the intended effect.
A pharma GTM strategy that operates as an integrated 5-layer system—rather than disconnected workstreams—creates a compounding advantage. Precise segmentation sharpens channel allocation, which delivers the right scientific message supported by a defensible payer argument and a logical sequencing model.
The Indian pharma market is no longer forgiving of reactive commercial planning. The question is no longer whether to build a structured framework, but whether to build it before launch—or to reverse-engineer it from the wreckage of a launch that did not deliver.
OneAlphaMed helps pharma brand managers and commercial leads build integrated GTM strategies across all five layers. Explore Go-To-Market & Product Launch →
A go-to-market strategy in pharma is an integrated commercial plan that defines how a brand will reach its target prescribers, communicate its clinical value, and capture market share at and after product launch. It connects patient segmentation, HCP targeting, channel mix, scientific messaging, payer access, and launch sequencing into a single coordinated system — rather than treating each element as an independent activity.
Most pharma launch underperformance in India traces back to three causes: poorly defined HCP targeting that drives promotional spend toward prescribers with low switching intent; a misaligned channel mix that over-relies on field force and neglects digital engagement; and insufficient payer access planning, which creates formulary or reimbursement barriers that were foreseeable but unaddressed. A structured GTM framework identifies and resolves all three before launch.
Launch sequencing defines the order in which GTM activities activate — ensuring that scientific exchange with specialists, KOL engagement, and payer access groundwork all precede commercial promotion. In India, sequencing must also account for DCGI regulatory timelines, NPPA pricing negotiation windows, and state-level tendering processes, which each carry defined lead times that affect commercial launch readiness.
Each layer carries India-specific considerations. Segmentation must incorporate tier-2 and tier-3 city disease burden data. Channel mix must account for rep access constraints in high-density urban markets and the digital preferences of a younger HCP cohort. Scientific messaging should incorporate Indian sub-group clinical data where available. Payer access must navigate PM-JAY formulary requirements and NPPA pricing caps. And launch sequencing must align with DCGI approval milestones and phased geographic rollout planning.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.
